1800 202 8726
Breast cancer pathology report

Ki-67 in Breast Cancer: — What Your Number Means

Ki-67 is a single number on your pathology report that tells your oncologist how actively your tumour cells were dividing. In hormone-positive breast cancer, it is one of the main factors that shapes the chemotherapy conversation.

Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed September 2026

  • A growth-rate marker — Ki-67 counts what percentage of tumour cells were actively dividing when your biopsy was taken.
  • Central to one key decision — In hormone-positive, HER2-negative breast cancer, Ki-67 directly influences whether chemotherapy is added to hormone therapy.
  • No single universal cut-off — Different guidelines use different thresholds, and your oncologist will tell you how your number sits against the one they follow.
  • Lab variation is real — The same tumour can produce a different Ki-67 at different laboratories — knowing why helps you ask better questions.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Get this explained properly

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

Ki-67 measures what percentage of your tumour cells were actively dividing at the time of biopsy. A higher number means faster-growing cells. In hormone-positive breast cancer, your Ki-67 result is one of the main factors your oncologist weighs when deciding whether chemotherapy is needed alongside hormone therapy.

What do these words on my pathology report mean?

Ki-67
A protein present only in cells that are actively dividing. The test counts what percentage of tumour cells stained positive for it, giving a proliferation percentage.
Proliferation index
Another name for the Ki-67 percentage. It describes how actively the tumour was reproducing itself at the moment of biopsy.
Low Ki-67
A smaller proportion of cells were dividing at biopsy. Generally associated with slower tumour growth and, in hormone-positive disease, a stronger case for hormone therapy alone.
High Ki-67
A larger proportion of cells were dividing. Associated with faster growth and more likely to prompt a discussion about adding chemotherapy.
Intermediate Ki-67
A result in the grey zone where the picture is less clear. Other factors — tumour size, lymph node involvement, grade, and sometimes gene expression tests — carry more weight here.

What else should I check on my pathology report?

  • Check your ER and PR status — Ki-67 most directly drives the chemotherapy discussion in hormone-positive, HER2-negative disease
  • Find your tumour grade (1, 2, or 3) — Ki-67 and grade usually align, and a mismatch is worth raising with your oncologist
  • Note which laboratory ran the test — results can vary between labs on the same tumour
  • Bring the full pathology report to your appointment, not just the Ki-67 number
  • Ask your oncologist which guideline they are using to interpret your result

Is there a single cut-off between high and low?

There is no single universally agreed threshold. ESMO and ASCO guidance both acknowledge that Ki-67 cut-off values have not been fully standardised.

Different expert consensus groups have proposed different thresholds over the years. The same result can be interpreted differently at different centres — not because either is wrong, but because the evidence for a precise cut-off is genuinely uncertain.

Results in the intermediate range are the most affected by this. Your oncologist may weigh other tumour features alongside Ki-67, or discuss whether gene expression testing would give a clearer picture.

Still unclear?

Send your reports across and a specialist will walk you through what they mean — what is known, what is not, and what the options actually are.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Get a straight answer from a specialist

45 minutes, your reports reviewed, your questions answered in plain language.

Book Free Consultation Call 1800 202 8726

How do high and low Ki-67 results typically differ?

FeatureLow Ki-67High Ki-67
Cell growth speedSlower-dividing cellsFaster-dividing cells
Grade associationCommonly Grade 1 or 2Commonly Grade 2 or 3
In the chemotherapy discussionA weaker argument for adding itA stronger argument for adding it
Hormone therapy aloneMore often considered sufficient in early-stage diseaseLess likely to be sufficient without further discussion

Why can the same tumour give a different Ki-67 at different labs?

Ki-67 is measured by a pathologist counting stained cells under the microscope, or using digital image analysis. The result depends on which area of the tumour is sampled, how the tissue was processed, which antibody was used, and how many cells were counted.

There is no single international standard for this measurement. ESMO guidance notes that results should be interpreted in the context of the laboratory that performed the test, because interlaboratory variability is a known limitation.

If your result falls close to any threshold, ask your oncologist directly: does the lab variability change the decision, or is the result clear enough that it does not?

Did you know?

Ki-67 was identified as a useful proliferation marker in the 1980s, yet standardising how it is measured across pathology laboratories worldwide remains an active area of work.

ESMO has called for better harmonisation of Ki-67 scoring methods in their early breast cancer guidelines — your pathologist is working with a measurement that oncologists and pathologists internationally are still working to make more consistent.

Source: ESMO Clinical Practice Guidelines: Early Breast Cancer

Explore 112 more Markers, Molecular Testing and Test Accuracy topics

HUB — How Accurate Is a Biopsy? Repeats, Errors and Second Opinions

HUB — IHC and Molecular Markers on a Biopsy

HUB — Labs, Slides and Second Opinions on a Biopsy

All Markers, Molecular Testing and Test Accuracy →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

What is considered a high Ki-67 in breast cancer?

There is no single number that marks the boundary between high and low, and this is the honest answer rather than an evasion. ESMO and ASCO guidance both acknowledge that no universally validated cut-off exists. Different expert groups have proposed different thresholds, and the same result can be read differently at different centres. What matters is how your oncologist interprets your number against the guideline they follow, alongside your other results. Ask them directly where your value sits and what it means for your treatment discussion.

Does a high Ki-67 mean I definitely need chemotherapy?

No. Ki-67 is one factor in that decision, not the only one. Your oncologist weighs it alongside your tumour stage, lymph node involvement, grade, ER and PR status, HER2 status, and your overall fitness. A high result makes the case for chemotherapy stronger, but it does not make the decision automatic. In some situations, gene expression tests are used alongside Ki-67 to reduce uncertainty. Your oncologist will explain what is driving their specific recommendation for you.

My Ki-67 is in the middle range — what happens now?

When Ki-67 falls in the middle range, your oncologist looks at the rest of your tumour's picture before deciding on treatment. They may consider your grade, tumour size, and lymph node status to see if they point in a clearer direction. They may also discuss whether a gene expression test would provide more information. Not every intermediate result leads to additional testing — the decision depends on your full picture. Ask what the other factors are pointing to and why.

Why is my Ki-67 different from a report done at another lab?

Ki-67 measurement has known interlaboratory variability. Different laboratories may use different antibodies, different tissue processing protocols, and different counting methods. A result near any threshold is the most likely to shift between labs. ESMO guidance specifically notes this limitation and recommends interpreting results in the context of the laboratory that performed the test. If two reports disagree significantly on a borderline result, raise it with your oncologist — it may not change the decision, but it is a legitimate question.

Can Ki-67 change between my biopsy and my surgery specimen?

Yes, and this is a documented finding in the research literature. The Ki-67 measured on a needle biopsy can differ from what is measured on the final surgical specimen, because the two samples come from different areas of the tumour and represent different amounts of tissue. Some oncologists use the surgical specimen result for treatment planning when it is available, as it represents a larger sample. If you have two Ki-67 results from different points in your workup, ask your oncologist which one they are using and why.

How does Ki-67 fit with my ER, PR, and HER2 results?

Each of the four markers — ER, PR, HER2, and Ki-67 — answers a different question about your tumour's biology, and your oncologist reads them as a set. ER and PR tell you whether the tumour is driven by hormones. HER2 tells you whether a specific growth receptor is overactive. Ki-67 tells you how fast the tumour was growing at biopsy. In hormone-positive, HER2-negative breast cancer, Ki-67 is particularly important because it helps distinguish tumours likely to respond to hormone therapy alone from those that may need more. Your oncologist interprets all four together.

Full index

Browse all 701 biopsy topics

Every page in this section, grouped by the part of the journey it belongs to. Pick a group to see what is in it.

What Is a Biopsy?

What Is a Biopsy? Everything You Need to Know →

Types of Biopsy Compared

Which Biopsy Will You Have? Techniques Compared →

Preparing for a Biopsy

What to Expect on the Day of Your Biopsy →

Recovery and Aftercare

After a Biopsy: Recovery, Aftercare and Warning Signs →

Biopsy by Body Part

Biopsy by Body Part: What to Expect at Each Site →

Understanding Your Report

How to Read a Biopsy Report: Terms Explained →

IHC and Molecular Markers

IHC and Molecular Markers on a Biopsy: What They Mean →

Grading and Scoring Systems

Cytology & Prostate Scoring Systems Explained →

How Accurate Is a Biopsy?

How Accurate Is a Biopsy? Errors and Second Opinions →

If Your Result Is Benign

Your Biopsy Is Benign: What It Means and What Comes Next →

Call now Book free consultation